Deals Of The Week: Bristol/Ono, Bristol/Ambrx, Merck Serono/Peptimmune
Executive Summary
Each week, “The Pink Sheet” presents commentary on some of the week’s most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at http://invivoblog.blogspot.com.
You may also be interested in...
Merck KGaA Signs Cancer-MS Barter Deal With Japan's Ono
Why pay cash if you can barter asset rights instead? In a duo of agreements announced Oct. 4, Germany's Merck KGaA licensed worldwide rights ex-Japan, Korea and Taiwan to Ono Pharmaceutical Co. Ltd.'s Phase II MS candidate, ONO-4641, while granting Ono Japanese rights to its own Phase III cancer immunotherapy Stimuvax
Merck KGaA Signs Cancer-MS Barter Deal With Japan's Ono
Merck Serono and Ono exchange rights to clinical programs in MS and cancer, with little cash changing hands
Merck KGaA Signs Cancer-MS Barter Deal With Japan's Ono
Merck Serono and Ono exchange rights to clinical programs in MS and cancer, with little cash changing hands